Table 4

Spearman's correlation coefficient of DAREA with disease activity variables and composite scores at baseline

IMPACT 21800.85***0.89***0.89***0.25**0.32***0.30***0.59***0.80***0.63***0.89***0.26**0.002; NS0.08; NS
IMPACT 2/DIP involvement400.89***0.93***0.93***0.12; NS0.25; NS0.54***0.66***0.80***0.71***0.84***0.15; NS0.10; NS0.27; NS
Observational/DIP involvement410.87***.87***0.97***0.94***0.73***0.71***0.45*0.41*0.57**0.45*0.71***0.69***NS0.52**0.50*
  • Given are correlation coefficients (Spearman's r).

  • * p<0.05,

  • ** p<0.01,

  • *** p<0.001.

  • SF-36 pf for IMPACT 2, HAQ for observational set;

  • DIP involvement: according to classification by Wright and Moll.3

  • CDAI, clinical disease activity index; CRP, C reactive protein; DAREA, ‘Disease Activity index for REactive Arthritis’; DAS28, disease activity score using 28 joint counts; DIP, distal interphalangeal joint; EGA, evaluator global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IMPACT 2, Infliximab Multinational Psoriatic Arthritis Controlled Trial 2; PASI, psoriasis area and severity index; PtGA, patient global assessments; SDAI, simplified disease activity index; SJC, swollen joint count; TJC, tender joint count.